---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: sunRIZE"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: sunRIZE. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 65 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence/sunrize"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: sunRIZE

<a id="heading-3.1.3"></a>

## 3.1.3 sunRIZE

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Objective in the ClinicalTrials.gov record

> “The Phase 3 pivotal study is designed to evaluate the efficacy and safety of RZ358 for the treatment of congenital hyperinsulinism (HI) as add-on to standard-of-care (SOC) therapy compared to SOC alone over 24 weeks and to evaluate the longer-term safety and efficacy of RZ358 during a subsequent open-label extension (OLE) period.”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.1-2"></a>

#### Objective and population stated by the company

> “The Phase 3 sunRIZE study (RZ358-301) is a multi-center, randomized, double-blind, placebo-controlled, parallel arm study designed to evaluate the efficacy and safety of ersodetug in patients with congenital hyperinsulinism (HI), ages 3 months to 45 years old, who are experiencing continued hypoglycemia on currently available standard of care (SOC).”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-3.1.3.1-3"></a>

#### Relevance of the congenital HI trial to tumor HI stated by the company

> “Based on historical precedent, supportive data from the sunRIZE study (i.e., safety and drug activity), the recent liberalization of the tumor HI study and differentiation between study endpoints, and the experience that we have reported”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2024-01-11”
> “Primary Completion (Actual) 2025-11-14”
> “Study Completion (Estimated) 2027-11-14”
> “First Posted 2024-01-17”
> “Last Update Posted 2026-01-08”
> “Active, not recruiting”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.2-2"></a>

#### Number of locations in the ClinicalTrials.gov record

> “This study has 18 locations”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.2-3"></a>

#### Study locations by country in the ClinicalTrials.gov record

| Country | Locations listed in the record |
| --- | --- |
| United States | “Philadelphia, Pennsylvania, United States, 19104”; “Fort Worth, Texas, United States, 76104” |
| Bulgaria | “Varna, Bulgaria, 9010” |
| Denmark | “Odense, Denmark, 5000” |
| France | “Bron, France, 69677”; “Paris, France, 75015” |
| Georgia | “Tbilisi, Georgia, 0159” |
| Germany | “Berlin, Germany, 13353”; “Düsseldorf, Germany, 40225” |
| Greece | “Athens, Greece, 115 27” |
| Oman | “Seeb, Oman, 123” |
| Qatar | “Al Rayyan, Qatar” |
| Spain | “Barcelona, Spain, 08035”; “Seville, Spain, 41013” |
| Turkey (Türkiye) | “Ankara, Turkey (Türkiye), 06800” |
| United Kingdom | “London, United Kingdom, WC1N 3JH”; “Manchester, United Kingdom, M13 9WL” |
| Vietnam | “Hà Nội, Vietnam, 100000” |

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.2-4"></a>

#### Countries and U.S. enrollment stated by the company

> “The study enrolled 63 participants in more than a dozen countries around the world, inclusive of U.S. patients.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-3.1.3.2-5"></a>

#### Completion of enrollment

> “which completed enrollment in May 2025”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-3.1.3.2-6"></a>

#### Announcement of topline results

> “REDWOOD CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT)”
> “today announced topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism (HI).”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Design in the ClinicalTrials.gov record

> “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ358 in Patients With Congenital Hyperinsulinism”
> “This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled (SOC alone), parallel-arm, efficacy, and safety study of RZ358 in participants with congenital HI who have not achieved adequate hypoglycemia control with reasonable attempts at using usual SOC medical therapy.”
> “Allocation : Randomized”
> “Masking Description: Double blind”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.3-2"></a>

#### Randomization scheme and open-label infant arm in the ClinicalTrials.gov record

> “The study will randomize approximately 48 participants (≥1 year to ≤45 years of age) in a 1:1 ratio into 2 dosing arms (5 or 10 mg/kg with) and further randomize participants within each dosing level in a 2:1 ratio to receive RZ358 as add-on to SOC or placebo as add-on to SOC.”
> “An additional open-label (OL) arm will be conducted in parallel for participants who are ≥3 months to <1 year old (n=8)”
> “Upon completion of the pivotal treatment period (24-weeks), participants may roll-over to the OLE period at the discretion of the investigator and Sponsor.”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.3-3"></a>

#### Treatment periods and open-label extension in the congress presentation

> “Double-Blind Comparator Control Groups”
> “Initial 8 patients ages 3 months – 1 yr enrolled in open-label arm (making total planned enrollment 56)”
> “Open Label Extension”
> “Long-term safety, efficacy durability, efficacy in monotherapy”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Inclusion criteria in the ClinicalTrials.gov record

> “At screening, aged ≥ 3 months and ≤ 45 years old.”
> “An established clinical diagnosis of congenital HI (hyperinsulinism), with or without identification of a known monogenic variant by genetic testing.”
> “Participant has failed to achieve adequate glycemic control with appropriate and reasonable trials of locally accepted and available Standard of Care (SOC) medical therapies (e.g., diazoxide and somatostatin analogs (SSAs)) per the judgment of the investigator.”
> “Experiencing ≥ 3 hypoglycemia events per week by screening Self-Monitoring Blood Glucose (SMBG) and average daily percent time with hypoglycemia of ≥ 8% of the monitored screening Continuous Glucose Monitor (CGM) time.”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.4-2"></a>

#### Exclusion criteria in the ClinicalTrials.gov record

> “Alanine aminotransaminase (ALT), aspartate aminotransaminase (AST), total bilirubin (TB), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT) ≥ 1.5 × the upper limit of normal for the age-specific reference range, regardless of assessed significance.”
> “A known clinical diagnosis of diabetes or pre-diabetes, or a history of insulin dependency within 3 months of screening.”
> “Average daily percent time with hyperglycemia ≥ 5% of the monitored screening continuous glucose monitoring (CGM) time.”
> “Known allergy or sensitivity to RZ358 or any component of the drug.”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.4-3"></a>

#### Body mass index exclusion in the ClinicalTrials.gov record

> “Body mass index (BMI) ≥ 35 kg/m2 for participants aged 18 years and above”
> “(no BMI exclusion for participants ≤ 12 years of age).”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.4-4"></a>

#### Key inclusion criteria in the congress presentation

> “Ages 3 months – 45 years”
> “Biochemically established diagnosis of cHI”
> “Persistent hypoglycemia despite SoC”
> “SMBG: >3 hypo (<70 mg/dL) per week”
> “CGM: >8% avg daily time <70 mg/dL”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Treatment arms in the ClinicalTrials.gov record

> “Participants ≥1 year old who receive SOC therapy and 5 mg/kg of RZ358 or placebo”
> “Participants ≥1 year old who receive SOC therapy and 10 mg/kg of RZ358 or placebo”
> “Infant participants from ≥3 months to <1 year old who receive SOC therapy + RZ358 starting at 5 mg/kg and increasing to 10 mg/kg of RZ358, as needed, per the protocol schedule”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.5-2"></a>

#### Dose, schedule, and background therapy stated by the company

> “Eligible participants are randomized to one of three treatment arms to receive either ersodetug (5 or 10 mg/kg) or matched placebo-control as add on to existing SOC. Study drug is administered every other week during an initial loading phase, and then every 4 weeks during the 6-month controlled pivotal treatment period.”
> “At the study dose regimens of 5 and 10 mg/kg administered every other week for 3 doses, followed by every 4 weeks over the remainder of the 24-week treatment duration”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-3.1.3.5-3"></a>

#### Route and infusion duration of ersodetug

> “30-min IV infusion given every 2-4 weeks”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.5-4"></a>

#### Dosing in the open-label extension

> “Following the pivotal treatment phase of the study, participants may roll-over into an optional open-label extension phase to continue to receive ersodetug.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

> “PI discretion: 5 or 10mg/kg dosing Q2-4 weeks, adjustment in SoC”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Weekly Hypoglycemia Events by Self-monitored Blood Glucose as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Primary outcome in the ClinicalTrials.gov record

> “Change in average weekly hypoglycemia events from baseline by point-of-care Self-Monitoring Blood Glucose (SMBG)”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.6.1-2"></a>

##### Key secondary outcome in the ClinicalTrials.gov record

> “Change in average daily percent time in hypoglycemia from baseline by Continuous Glucose Monitor (CGM)”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.6.1-3"></a>

##### Primary and key secondary endpoints stated by the company

> “The primary and key secondary efficacy endpoints in the study are the change from baseline in the average number of hypoglycemia events per week and the average percent time in hypoglycemia, respectively, over six months of treatment.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-3.1.3.6.1-4"></a>

##### Other glycemic outcomes in the ClinicalTrials.gov record

> “Proportion of participants experiencing no potentially serious hypoglycemia events by SMBG.”
> “Change in average weekly incidence of potentially serious hypoglycemia events by Self-Monitoring Blood Glucose (SMBG).”
> “Change in average daily percent time with potentially serious hypoglycemia by Continuous Glucose Monitor (CGM).”
> “Change in average 8-hour overnight percent time with hypoglycemia by CGM.”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.6.1-5"></a>

##### Safety outcomes in the ClinicalTrials.gov record

> “Hepatic ultrasound: evaluated for significant structural changes (e.g. peliosis Hepatitis)”
> “Immunogenicity assessments: Blood samples for anti-drug antibody to RZ358 will be evaluated based on the titer, and potential neutralization effects.”
> “24 weeks, plus up to two years of Open-Label Extension (OLE) period”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.6.1-6"></a>

##### Limitations of self-monitored blood glucose metrics acknowledged by the FDA

> “FDA acknowledged the challenges posed by the potential impact of varied behavioral factors on clinical trials in this heterogeneous patient population, including the associated limitations of self-monitored blood glucose (SMBG) based metrics in measuring hypoglycemia in congenital HI.”
> “While acknowledging these challenges, the agency reiterated the expectation for adequate and well-controlled studies and outcomes as the standard for evaluating substantial evidence of efficacy criteria as the basis for approving new therapies.”

Source: [Rezolute congenital HI FDA meeting release (2026)](https://ir.rezolutebio.com/news/detail/373/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting)

<a id="topic-3.1.3.6.1-7"></a>

##### Unblinded self-monitored glucose as a source of bias stated by the company

> “The Company believes that the unblinded nature of self-monitored glucose necessary for patient standard of care, together with perceptions of treatment assignment, may have led to divergent behaviors between treatment groups during the study, which may have impacted the measurement of hypoglycemia by SMBG.”

Source: [Rezolute congenital HI FDA meeting release (2026)](https://ir.rezolutebio.com/news/detail/373/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting)

> “with a particular impact on the primary endpoint of hypoglycemia events by SMBG due to measurement bias associated with infrequent measurement”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-3.1.3.6.1-8"></a>

##### Glucose monitoring as both safety tool and endpoint in an ambulatory trial

> “The magnitude of the placebo response observed for hypoglycemia events reveals a significant challenge in studying glucose in an ambulatory setting, where factors such as intensive monitoring where caregivers receive alerts regarding hypoglycemic events and frequent clinical interactions can independently influence outcomes.”
> “The Company believes that the extent of reduction from baseline in hypoglycemia events and time in hypoglycemia relative to placebo (see Figure 2) may have been impacted by the prolonged treatment duration of six months and the fact that glucose monitoring is necessary for safe patient management while also serving as the key endpoint in the study.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.3.6.1-9"></a>

##### Key secondary endpoint: percent time in hypoglycemia by continuous glucose monitoring

> “Primary endpoint (SMBG weekly hypoglycemia events) not met”
> “Likely influenced by caregiver behavioral adaptations in hypoglycemia avoidance”
> “CGM metrics showed consistent and clinically meaningful reductions in hypoglycemia”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.6.1-10"></a>

##### Contrast with the inpatient glucose infusion rate endpoint of the tumor HI trial

> “Notably, the GIR assessment in the EAP is the primary endpoint in upLIFT, which measures the number of participants (out of ~16) who achieve at least a 50% reduction in GIR, an objective endpoint in a highly controlled hospital setting.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Planned power for the primary endpoint

> “Powered to show at least a 35% difference between each treatment arm and placebo”

Source: [Rezolute investor event presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925109559/tm2530840d1_ex99-1.htm)

<a id="topic-3.1.3.7.1-2"></a>

##### Planned enrollment in the ClinicalTrials.gov record

> “Enrollment (Estimated) 56”
> “The study will randomize approximately 48 participants (≥1 year to ≤45 years of age)”

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215)

<a id="topic-3.1.3.7.1-3"></a>

##### Planned and actual enrollment stated by the company

> “Overall enrollment of 63 participants exceeded target of 56”

Source: [Rezolute investor event presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925109559/tm2530840d1_ex99-1.htm)

<a id="topic-3.1.3.7.1-4"></a>

##### Participants by treatment group

> “RZ358 5 mg/kg (N=18)”
> “RZ358 10 mg/kg (N=20)”
> “Placebo (N=17)”
> “Overall [+OLA] (N=63)”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.7.1-5"></a>

##### Participants in the per protocol set

> “in the Per Protocol Set (PPS)* (n=41)”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

##### Analysis window and effect measure

> “at the defined Week 24 evaluable window”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

> “Outcomes (LS-Mean [95% CI] Percent Change from Baseline; FAS Population)”
> “Not statistically significant at SAP-specified Week 24/EOT analysis window (-32%; p=0.30 at 10 mg/kg)”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.7.2-2"></a>

##### Pre-specified, post-hoc, and sensitivity analyses submitted to the FDA

> “In June 2026, the Company submitted source and analysis datasets, and summary results from a substantial number of pre-specified, post-hoc, and sensitivity analyses.”

Source: [Rezolute pre-BLA recommendation release (2026)](https://ir.rezolutebio.com/news/detail/385/rezolute-announces-fda-recommendation-to-hold-a-pre-bla-meeting-as-a-precursor-to-submitting-a-biologics-license-application-bla-for-congenital-hyperinsulinism)

<a id="topic-3.1.3.7.2-3"></a>

##### Per protocol set

> “Per-Protocol Set (PPS): Defined in blinded fashion prior to database lock and excludes participants with below threshold SMBG/CGM data collection, significant escalation in background SOC, and early discontinuations.”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.7.2-4"></a>

##### Full analysis set

No evidence found.

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### Completion of the controlled period and entry into the open-label extension

> “All 59 participants who completed the study elected to continue to receive ersodetug in the OLE.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.3.8.1-2"></a>

##### Early terminations due to adverse events

> “4 early terminations due to adverse events (2 serious hypersensitivity reactions, 1 infusion reaction, 1 mild hypertrichosis)”

Source: [Rezolute January corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-3.htm)

<a id="topic-3.1.3.8.1-3"></a>

##### Retention in the open-label extension, January 2026

> “To date, 57 participants remain in the OLE, with an exposure duration ranging from ~6 weeks for the most recently entered patients, to ~18 months.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.3.8.1-4"></a>

##### Retention in the open-label extension, June 2026

> “All 59 participants rolled-over into the open-label extension after the pivotal treatment period”
> “57 still ongoing”
> “Cumulative duration of OLE participation: ~7-25 months”

Source: [ENDO Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/ENDO_2026_ORF10_sunRIZE_Demirbilek_13June.pdf)

<a id="topic-3.1.3.8.1-5"></a>

##### Retention in the open-label extension, September 2026

> “To date, 56 participants remain in the OLE, with an exposure duration ranging from ~9 months for the most recently entered patients, to more than 24 months.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

> “which had 56 participants continuing on the open-label extension as of September 30, 2026.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-3.1.3.8.1-6"></a>

##### Treatment duration in the open-label extension, November 2026

> “The OLE phase of the study is ongoing, with a continued high retention rate, equating to an ersodetug treatment duration in sunRIZE from approximately one year to well over two years.”

Source: [Rezolute prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926126478/tm2627558-6_424b5.htm)

<a id="topic-3.1.3.8.1-7"></a>

##### Planned conclusion of the open-label extension

> “The OLE phase of sunRIZE remains ongoing at the present time, but we are evaluating the appropriate timing to conclude the sunRIZE study OLE and move patients into its EAP, depending in part on outcomes from pending FDA interactions”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

##### Demographics, background therapy, and baseline glycemia of the enrolled population

| Parameter | Ersodetug 5 mg/kg | Ersodetug 10 mg/kg | Placebo | Overall, including open-label arm |
| --- | --- | --- | --- | --- |
| Number of participants | “(N=18)” | “(N=20)” | “(N=17)” | “(N=63)” |
| Age in years, mean (range) | “3.4 (1-15 y)” | “3.9 (5 mo to 9 y)” | “4.0 (5 mo to 10 y)” | “3.4 (3 mo to 15 y)” |
| Female, n (%) | “8 (44%)” | “10 (50%)” | “7 (41%)” | “31 (49%)” |
| Genetics, KATP / other or unknown, n (%) | “13 (72%) / 5 (28%)” | “11 (55%) / 9 (45%)” | “15 (88%) / 2 (12%)” | “47 (75%) / 16 (25%)” |
| Current standard of care therapy | “17 (94%)” | “18 (90%)” | “17 (100%)” | “60 (95%)” |
| Diazoxide, n (%) | “9 (50%)” | “11 (55%)” | “5 (29%)” | “26 (41%)” |
| Somatostatin analog, n (%) | “10 (56%)” | “11 (55%)” | “14 (82%)” | “46 (73%)” |
| Scheduled enteral tube feeding, n (%) | “7 (39%)” | “7 (35%)” | “7 (41%)” | “24 (38%)” |
| Two or more therapies, n (%) | “8 (44%)” | “9 (45%)” | “8 (47%)” | “29 (46%)” |
| Pancreatectomy, n (%) | “2 (11%)” | “3 (15%)” | “2 (12%)” | “8 (13%)” |
| Pre-study use of CGM, n (%) | “8 (44%)” | “11 (55%)” | “9 (53%)” | “32 (51%)” |
| Congenital HI-related hospitalizations in previous year, n (%) | “6 (33%)” | “12 (66%)” | “10 (59%)” | “32 (51%)” |
| Hypoglycemia events per week by SMBG, mean (range) | “12.7 (5-42.0)” | “13.4 (4-37)” | “11.7 (3-22)” | “12.6 (3-42)” |
| Percent time in hypoglycemia by CGM, mean (range) | “23.1 (5-73)” | “20.0 (6-71)” | “13.0 (7-38)” | “19.1 (5-73)” |
| HbA1c, mean % (range) | “4.96 (3.9-5.9)” | “5.01 (3.9-6.0)” | “5.32 (4.2-6.2)” | Not reported |
| Average glucose by SMBG, mean mg/dL | “81” | “82” | “86” | Not reported |
| Hypoglycemia Fear Survey worry score, mean | “27.1” | “28.2” | “34.6” | Not reported |

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.8.2-2"></a>

##### Preliminary baseline summary reported in November 2025

> “Average age of 3.4 years (range: 3m – 15y)”
> “Average of 15 hypoglycemia events/week by SMBG”
> “Average daily percent time in hypoglycemia on CGM of 19%”
> “40% on DZ”
> “67% on SSAs”
> “13% had previous pancreatectomy”

Source: [Rezolute investor event presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925109559/tm2530840d1_ex99-1.htm)

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

##### Primary endpoint: weekly hypoglycemia events by self-monitored blood glucose not met

> “The study did not meet its primary endpoint, which assessed change in the average weekly hypoglycemia events by self monitored blood glucose. There was an approximate 45% reduction in hypoglycemia events observed at the top ersodetug dose (10 mg/kg), which was not statistically significant compared to the placebo group, which experienced a 40% improvement.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

> “Study Effect on Unblinded SMBG Occurred Early in Dosing:”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.8.3-2"></a>

##### Key secondary endpoint: percent time in hypoglycemia by continuous glucose monitoring not met

> “Furthermore, the study did not meet its key secondary endpoint, which assessed change in average daily percent time in hypoglycemia by continuous glucose monitoring (CGM). At the 10 mg/kg dose of ersodetug, an approximate 25% reduction in time in hypoglycemia was observed, which was not statistically significant compared to the placebo, which increased by approximately 5%.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

> “Not statistically significant at SAP-specified Week 24/EOT analysis window (-32%; p=0.30 at 10 mg/kg)”
> “p=0.44”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.8.3-3"></a>

##### Percent time in hypoglycemia by continuous glucose monitoring at earlier time points, full analysis set

> “Reductions of >50% compared to placebo with nominal statistical significance at the noted timepoints”
> “# Significant reduction vs PBO (p<0.05; both doses) at Week 16;”
> “p≤0.1 at Weeks 8 (both doses) and 20 (5 mg/kg)”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.8.3-4"></a>

##### Percent time in hypoglycemia by continuous glucose monitoring, per protocol set

> “Reductions of ~60-80% compared to placebo with nominal statistical significance at the noted timepoints”
> “Not statistically significant at SAP-specified Week 24/EOT analysis window (-55%; p=0.18 at 10 mg/kg)”
> “p=0.28”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.8.3-5"></a>

##### Pre-specified and post-hoc continuous glucose monitoring endpoints

> “Average weekly hypoglycemia events by CGM : clinically relevant and nominally statistically significant reductions of ~50-65% (FAS) and ~50-80% (PPS), compared to placebo across multiple timepoints”
> “Average daily AUC 70 to 180 mg/dL (Exposure to Normoglycemia) by CGM : clinically relevant and nominally statistically significant increases of ~25-50% (FAS and PPS), compared to placebo across multiple timepoints”
> “Average blood glucose (mg/dL) by CGM : clinically relevant and nominally statistically significant increases of ~10-15% (~10-15 mg/dL) in both the FAS and PPS, compared to placebo across multiple timepoints”

Source: [Rezolute sunRIZE PES presentation release (2026)](https://ir.rezolutebio.com/news/detail/375/rezolute-announces-oral-presentation-of-results-from-its-phase-3-sunrize-study-of-ersodetug-in-patients-with-congenital-hyperinsulinism-at-the-pediatric-endocrine-society-annual-meeting)

> “including but not limited to 50% or greater reductions in both average daily percent time in hypoglycemia and average weekly hypoglycemia events.”

Source: [Rezolute FDA review update release (2026)](https://ir.rezolutebio.com/news/detail/383/rezolute-provides-update-on-fda-review-of-its-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-3.1.3.8.3-6"></a>

##### Drug concentrations and insulin biomarker response

> “At the study dose regimens of 5 and 10 mg/kg administered every other week for 3 doses, followed by every 4 weeks over the remainder of the 24-week treatment duration, ersodetug target drug concentrations were achieved, across all age groups studied.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

> “Specifically, there was evidence of pharmacologic activity as target therapeutic drug concentrations were achieved in both treatment groups (5 mg/kg and 10 mg/kg) with highly sensitive biomarker responses (increases in circulating insulin) in the active treatment groups that are indicative of reduced insulin activity at its receptor.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.3.8.3-7"></a>

##### Preliminary open-label extension observations

> “Glycemic improvement from baseline across multiple endpoints (e.g. average glucose by SMBG, hypoglycemia events by SMBG, HbA1c)”
> “Notably also in the rolled-over placebo participants compared to the controlled period of the study”
> “Concurrent overall reduction in background SoC (e.g, diazoxide, somatostatin analogs, and/or regular tube feeds)”
> “Including discontinuation of other therapies and use of ersodetug in monotherapy in many instances”
> “Data preliminary and in flux in ongoing OLE”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.8.3-8"></a>

##### FDA Type B meeting on the efficacy results, March 2026

> “As a next step for the program, FDA encouraged the Company to submit study reports and analysis datasets for the agency’s independent evaluation. Following that review, the Company believes that a determination may be made whether there is sufficient evidence to support the submission of a marketing application for sunRIZE or if additional information is required.”

Source: [Rezolute congenital HI FDA meeting release (2026)](https://ir.rezolutebio.com/news/detail/373/rezolute-provides-update-on-its-congenital-hyperinsulinism-program-following-fda-meeting)

<a id="topic-3.1.3.8.3-9"></a>

##### FDA review of the submitted datasets and pre-BLA recommendation, October 2026

> “The Agency has reviewed the data and, despite the trial’s failure to meet the prespecified primary and key secondary endpoints, as a next step, encouraged the Company to request a Type B pre-BLA meeting as a precursor to submitting a BLA for congenital HI. The Agency explicitly did not opine on the approvability of ersodetug for congenital HI and noted that any such determination would only be made as a part of an in-depth evaluation of the supporting data during a formal BLA review, as is customary during a BLA process.”

Source: [Rezolute pre-BLA recommendation release (2026)](https://ir.rezolutebio.com/news/detail/385/rezolute-announces-fda-recommendation-to-hold-a-pre-bla-meeting-as-a-precursor-to-submitting-a-biologics-license-application-bla-for-congenital-hyperinsulinism)

<a id="topic-3.1.3.8.3-10"></a>

##### Timing of the pre-BLA meeting and possibility of a further randomized study

> “The Company expects to request a pre-BLA meeting with the Agency to take place during the first half of calendar year 2027.”
> “The FDA may require us to provide additional information or conduct additional clinical studies, including another study similar to sunRIZE, which could delay the submission or approval of a BLA, increase our costs and require changes to our operating plans.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-3.1.3.8.3-11"></a>

##### Possible effect of the sunRIZE results on the FDA assessment of the tumor HI trial

> “we have previously asked the FDA whether it will consider the results of the sunRIZE trial when considering additional regulatory steps related to ersodetug, including whether the results of the sunRIZE trial will impact the FDA’s assessment of any results that we may receive from the upLIFT trial.”
> “Although the FDA has not historically grouped trial results in this way, in the event the FDA takes this approach in connection with ersodetug this could significantly impact our business and future plans.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

##### Patient-reported quality of life outcomes under evaluation

> “The Company is currently exploring how to characterize the overall study dynamic including evaluating patient-reported quality of life outcomes.”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-3.1.3.8.4-2"></a>

##### Patient and family experience in the open-label extension

> “Favorable patient/family reported experiences overall”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

##### Overall adverse events and adverse drug reactions

> “Adverse events occurred in ~90% of participants at a comparable rate across treatment groups”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

> “Safety observations from the study were generally favorable and, in the opinion of the Company, support safe use of ersodetug in pediatric and adult patients.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-3.1.3.8.5-2"></a>

##### Hypersensitivity reactions

> “Two of the study participants experienced serious hypersensitivity reactions which led to early discontinuation of study drug. The incidence of serious allergic reactions across the program is relatively low compared to biologic or monoclonal antibody treatments.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

> “Hypersensitivity reactions led to early discontinuation of study drug in 3 participants”
> “Two participants with serious allergic reactions (including anaphylaxis)”
> “Resolved quickly upon discontinuation of study drug”
> “Overall program incidence of ~2%”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.8.5-3"></a>

##### Hypertrichosis

> “The most commonly reported study adverse event in ersodetug treated participants compared to placebo was hypertrichosis, which was generally mild and self-limiting.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

> “Hypertrichosis was the only other commonly reported AE in ersodetug patients (n=14; 36%)”

Source: [Rezolute January corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-3.htm)

> “Excess hair growth (hypertrichosis) was commonly reported in ersodetug treated patients (~35%)”
> “Mild and not dose-dependent”
> “Led to discontinuation of study drug in 1 participant”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

<a id="topic-3.1.3.8.5-4"></a>

##### Hyperglycemia and hepatic safety

> “No clinically-relevant hyperglycemia:”
> “Low rates of transient mild to moderate hyperglycemia without associated sequalae”
> “No hyperglycemia AEs”
> “Hepatic safety: No signal by liver enzymes or ultrasound monitoring”

Source: [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf)

> “No liver safety signals”

Source: [Rezolute January corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-3.htm)

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary

- Population: sunRIZE enrolled participants with congenital hyperinsulinism aged 3 months to 45 years, a different disease and a younger population than adults with tumor hyperinsulinism, so its efficacy results are indirect evidence for this report. Its main relevance here is the safety data and its effect on the regulatory assessment.
- Outcome: the trial did not meet its primary or key secondary endpoint. The favorable continuous glucose monitoring results at earlier time points and in the per protocol set are nominal, and the company's explanation of the result (self-monitored measures confounded by functional unblinding through real-time glucose monitoring) is its own interpretation.
- Reporting: results are available only from company releases, filings, and congress slides, with no peer-reviewed publication. Sources differ on the number of discontinuations for hypersensitivity (2 serious reactions in the topline release; 3 participants in the congress slides; 4 early terminations in the January 2026 presentation), on the CGM result at 10 mg/kg (“approximate 25% reduction” against “-32%; p=0.30”), and on hypertrichosis (36% and about 35%). One baseline cell reads “12 (66%)” for 12 of 20 participants. The registry still lists an estimated enrollment of 56.
- The open-label extension is ongoing, and its glycemic observations are described by the company as preliminary.

Source: [ClinicalTrials.gov NCT06208215](https://clinicaltrials.gov/study/NCT06208215); [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism); [Pediatric Endocrine Society Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/05/Rezolute_De_Leon_May1_Final_2.pdf); [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism); [Rezolute January corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-3.htm)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
